We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

By HospiMedica International staff writers
Posted on 19 Dec 2022
Print article
Image: Detecting SARS-CoV-2 with a new Quenchbody immunosensor (Photo courtesy of Tokyo Tech)
Image: Detecting SARS-CoV-2 with a new Quenchbody immunosensor (Photo courtesy of Tokyo Tech)

The incredibly fast spread of COVID-19 throughout the world brought to light a very important fact: we need better methods to diagnose infectious diseases quickly and efficiently. During the early months of the pandemic, polymerase chain reaction (PCR) tests were one of the most widely used techniques to detect COVID-19. However, these viral RNA-based techniques require expensive equipment and reaction times longer than an hour, which renders them less than ideal for point-of-care testing. The limitations of PCR fueled the development of various immunoassay methods, which use specially engineered antibodies to detect SARS-CoV-2 antigens with high sensitivity in little time. Today, scientists are still improving immunoassay technology to make available tools more convenient, sensitive, and cost-effective. Against this backdrop, a team of researchers has developed a new immunosensor based on Quenchbody technology that shows great potential as a fast, inexpensive, and convenient tool to detect SARS-CoV-2. This highly efficient diagnostic approach will be useful not only for point-of-care testing, but also for high-throughput epidemiological studies of COVID-19 and other emerging infectious diseases.

The team of researchers at Tokyo Institute of Technology (Tokyo Tech, Tokyo, Japan) has not only developed a new Quenchbody fluorescent immunosensor that can detect SARS-CoV-2 with exceptional speed and sensitivity, but also created a simple way to greatly enhance the immunosensor's performance using a crowding agent. A Quenchbody is a molecular sensor originally developed by Professor Ueda and colleagues using antibody fragments and fluorescent tags. The antibody fragment, which can be an antigen-binding region (or 'Fab'), targets a specific viral molecule (antigen). Meanwhile, the fluorescent tags are small fluorescent dye molecules attached by a peptide linker to the Quenchbody, near the antigen-binding region. When the antigen is absent, the fluorescent tags are attracted to the Fab and intrinsic amino acids (mainly tryptophan) interact with the dyes and quench the fluorescence. However, when the antigen appears, it replaces the fluorescent tag at the Fab, causing it to move away and recover its fluorescence. Thus, in a Quenchbody test, an increase in fluorescence indicates the detection of the target antigen.

In this study, the research team developed a double-tagged Quenchbody targeting the nucleocapsid protein (N protein) of SARS-CoV-2. To take things one step further, they also tested whether various commercially available compounds could improve the immunosensor's sensitivity and detection time. In particular, adding polyethylene glycol 6000 (PEG6000) at the right concentration as a crowding agent increased performance quite significantly. To further validate their approach, the team tested their immunosensor on leftover clinical samples from COVID-19 positive patients. After careful analysis of the results, they concluded that their newly developed Quenchbody could measure N protein more easily and quantitatively than a commercial lateral flow antigen test.

"Our work shows the feasibility of using Quenchbody immunosensors as rapid and cost-efficient tools for the diagnosis and high-throughput analysis of swab samples in large-scale monitoring and epidemiological studies of COVID-19, as well as other emerging infectious diseases," said Professor Hiroshi Ueda at Tokyo Tech who led the research.

Related Links:
Tokyo Tech

Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
New
Wound Dressing
Thin Absorbent Wound Dressing Featuring TASA
New
Electric Gynecological Operating Table
YF-6
New
Mobile X-Ray Table
X Mobil

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: New technology gives patients the power to heal chronic wounds using their own blood (Photo courtesy of RedDress)

POC Solution Creates In Vitro Blood Clots from Patient’s Own Whole Blood in Real-Time to Treat Post-Surgical Wounds

Blood clots are a natural mechanism of the body's healing process. However, for chronic wounds resulting from diabetes and other conditions, blood is unable to reach these areas, hampering the initiation... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.